Biosplice Therapeutics, Inc.
🇺🇸United States
Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
Phase 1
Completed
- Conditions
- Hepatic CancerGastric CancerColorectal CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02191761
Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)
Phase 1
Completed
- Conditions
- Moderate to Severe Osteoarthritis
- Interventions
- Drug: SM04690, 0.23mg/2mLDrug: SM04690, 0.03mg/2mLDrug: SM04690, 0.07mg/2mLDrug: Placebo
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT02095548
© Copyright 2025. All Rights Reserved by MedPath